A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)

Clinical trial NCT05282953 · COMPLETED

Trial details

NCT number: NCT05282953
Sponsor: Kiora Pharmaceuticals, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Retinitis Pigmentosa Choroideremia Non-Syndromic Rod-Dominant Inherited Retinal Diseases

Start date: 2022-11-10
Primary completion: 2023-08-10
Enrollment: 32

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.